Annie Guérin
![Annie Guérin](/globalassets/experts-and-consultants/managing-principals/guerin_annie.jpg)
Education
M.S. and B.S., economics, Université de Sherbrooke
Summary of Experience
Ms. Guérin is an economist who specializes in the application of statistics and econometrics to health economics and outcomes research (HEOR) and epidemiology. Her areas of expertise include retrospective database analyses such as medical claims, electronic health records, and clinical trial data; economic modeling, such as cost-effectiveness and budget impact models; and design of chart review studies, surveys, and other prospective studies. She has participated in the development of large clinical data registries and in the design of real-world evidence (RWE) studies to support regulatory submissions. Ms. Guérin has broad research and analytical experience in areas such as comparative effectiveness and cost effectiveness, development of prediction algorithms, assessment of disease prevalence and incidence, evaluation of burden of illness, productivity loss, treatment patterns, analysis of patient-reported outcomes (PROs), safety/tolerability analyses, discrete choice experiments, and patient experience studies. She has also supported many pharmaceutical companies in the development of HEOR planning and RWE generation plans. Ms. Guérin has conducted health care research across many therapeutic areas, including oncology, hematology, dermatology, gastroenterology, rheumatology, neurology, psychiatry, endocrinology, cardiology and circulatory diseases, and respiratory diseases. She publishes frequently and is the coauthor of over 100 research papers published in numerous peer-reviewed journals and presented at a variety of scientific conferences.
-
Comorbidities and Prescribed Medications in Patients With or Without Dry Eye Disease: A Population-Based Study
American Journal of Ophthalmology. 2019 Feb;198:181-192
2024Dana R, Bradley JL, Guérin A, Pivneva I, Evans AM, Stillman IÖ
HEOR, Epidemiology & Market Access -
A real-world assessment of healthcare costs associated with agitation in Alzheimer’s dementia
Journal of Medical Economics, 2024
2024Grossberg G, Urganus A, Schein J, Bungay R, Cloutier M, Gauthier-Loiselle M, Chan D, Guerin A, Aggarwal J
HEOR, Epidemiology & Market Access -
Patient journey of civilian adults diagnosed with posttraumatic stress disorder—A chart review study
Current Medical Research and Opinion, 2024
2024Davis LL, Urganus A, Gagnon-Sanschagrin P, Maitland J, Bedard J, Bellefleur R, Cloutier M, Guérin A, Aggarwal J
HEOR, Epidemiology & Market Access -
Real-world clinical outcomes and healthcare costs in patients with Crohn's disease treated with vedolizumab versus ustekinumab in the United States
Current Medical Research and Opinion, 2024
2024Chiorean M, Jiang J, Candela N, Chen G, Romdhani H, Latremouille-Viau D, Shi S, Bungay R, Guerin A, Fan T
HEOR, Epidemiology & Market Access -
Stratified Patient Profiling for Vedolizumab Effectiveness in Crohn's Disease: Identifying Optimal Subgroups for Enhanced Treatment Response in the EVOLVE Study
Advances in Therapy, 2024
2024Yarur A, Mantzaris GJ, Wang S, Adsul S, Kamble P, Cook E, Sajeev G, Guerin A, Bressler B
HEOR, Epidemiology & Market Access -
Treatment-Free Interval: A Novel Approach to Assessing Real-World Treatment Effectiveness and Economic Impact Among Patients with Irritable Bowel Syndrome with Diarrhea
Advances in Therapy, 2024
2024Lacy B, Gagnon-Sanschagrin P, Heimanson Z, Bungay R, Bellefleur R, Guérin A, Bumpass B, Borroto D, Joseph G, Dashputre A
HEOR, Epidemiology & Market Access -
Patient preferences for treatment attributes in moderate-to-severe atopic dermatitis: a discrete choice experiment
Journal of Dermatological Treatment, 2024
2024Feldman SR, Guérin A, Gauthier-Loiselle M, Claxton AJ, Hazra NC, Meng Y, Gallant K, Balu S
HEOR, Epidemiology & Market Access, Surveys & Experimental Studies -
Clinical and economic burden of medicare beneficiaries with multiple myeloma and renal impairment: An observational study
Medicine, 2024
2024Hari P, Latrémouille-Viau D, Lin P, Guérin A, Sasane M
HEOR, Epidemiology & Market Access -
Healthcare resource utilization and costs associated with psychiatric comorbidities in pediatric patients with attention-deficit/hyperactivity disorder: a claims-based case-cohort study
Child and Adolescent Psychiatry and Mental Health, 2024
2024Schein J, Cloutier M, Gauthier-Loiselle M, Bungay R, Chen K, Chan D, Guerin A, Childress A
HEOR, Epidemiology & Market Access -
The economic impact of suboptimal treatment and treatment switch among patients with Crohn's disease treated with a first-line biologic - A US retrospective claims database study
Journal of Medical Economics, 2024
2024Gagnon-Sanschagrin P, Sanon M, Davidson M, Willey C, Kachroo S, Hoops T, Naessens D, Guerin A, Cloutier M
HEOR, Epidemiology & Market Access -
Healthcare Resource Utilization and Costs Among Patients With Gastroesophageal Reflux Disease, Barrett’s Esophagus, and Barrett’s Esophagus-Related Neoplasia in the United States
Journal of Health Economics Outcomes Research, 2023
2023Sharma P, Falk GW, Bhor M, Ozbay AB, Latrémouille-Viau D, Guérin A, Shi S, Elvekrog MM, Limburg P
HEOR, Epidemiology & Market Access -
Real-world upper endoscopy utilization patterns among patients with gastroesophageal reflux disease, Barrett esophagus, and Barrett esophagus-related esophageal neoplasia in the United States
Medicine, 2023
2023Sharma P, Falk GW, Bhor M, Ozbay AB, Latrémouille-Viau D, Guérin A, Shi S, Elvekrog MM, Limburg P
HEOR, Epidemiology & Market Access -
Treatment Discontinuation Patterns for Patients with Chronic Lymphocytic Leukemia in Real-World Settings: Results from a Multi-Center International Study
Clinical Lymphoma, Myeloma & Leukemia, 2023
2023Shadman M, Manzoor BS, Sail K, Tuncer HH, Allan JN, Ujjani C, Emechebe N, Kamalakar R, Coombs CC, Leslie L, Barr PM, Brown JR, Eyre TA, Rampotas A, Schuh A, Lamanna N, Skarbnik A, Roeker LE, Bannerji R, Eichhorst B, Fleury I, Davids MS, Alhasani H, Jiang D, Hill BT, Schuster SJ, Brander DM, Pivneva I, Burne R, Guerin A, Mato AR
HEOR, Epidemiology & Market Access -
Treatment Patterns among Patients with Attention-Deficit/Hyperactivity Disorder and Comorbid Anxiety and/or Depression in the United States: A Retrospective Claims Analysis
Advances in Therapy, 2023
2023Schein J, Childress A, Gagnon-Sanschagrin P, Maitland J, Bedard J, Cloutier M, Guérin A
HEOR, Epidemiology & Market Access -
Patient journey before and after a formal post-traumatic stress disorder diagnosis in adults in the United States - a retrospective claims study
Current Medical Research and Opinion, 2023
2023Davis LL, Urganus A, Gagnon-Sanschagrin P, Maitland J, Qu W, Cloutier M, Guérin A, Aggarwal J
HEOR, Epidemiology & Market Access -
Risk factors associated with newly diagnosed attention-deficit/hyperactivity disorder in adults: a retrospective case-control study
BMC Psychiatry, 2023
2023Schein J, Cloutier M, Gauthier-Loiselle M, Bungay R, Arpin E, Guerin A, Childress A
HEOR, Epidemiology & Market Access -
Impact of rifaximin use following an initial overt hepatic encephalopathy hospitalization on rehospitalization and costs
Journal of Medical Economics, 2023
2023Jesudian AB, Gagnon-Sanschagrin P, Heimanson Z, Bungay R, Chen J, Guérin A, Bumpass B, Borroto D, Joseph G, Dashputre AA
HEOR, Epidemiology & Market Access -
CML-475 Real-World Treatment Patterns Among Patients With Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Cycling Through Multiple Tyrosine Kinase Inhibitors (TKIs) in the United States (US)
Clinical Lymphoma, Myeloma & Leukemia, 2022
2022Kota V, Maegawa R, Latremouille-Viau D, Jadhav K, Rossi C, Guérin A, Lorga S
HEOR, Epidemiology & Market Access -
Symptoms associated with ADHD/treatment-related adverse side effects and their impact on quality of life and work productivity in adults with ADHD
Current Medical Research and Opinion, 2022
2022Schein J, Cloutier M, Gauthier-Loiselle M, Bungay R, Guerin A, Childress A
HEOR, Epidemiology & Market Access -
Identifying Individuals with Undiagnosed Post-Traumatic Stress Disorder in a Large United States Civilian Population – A Machine Learning Approach
BMC Psychiatry, 2022
2022Gagnon-Sanschagrin P, Schein J, Urganis A, Serra E, Liang Y, Musingarimi P, Cloutier M, Guérin A, Davis L
Data Science & Statistical Modeling, Health Care, HEOR, Epidemiology & Market Access -
Chronic Myeloid Leukemia: Part I-Real-World Treatment Patterns, Healthcare Resource Utilization, and Associated Costs in Later Lines of Therapy in the United States
Journal of Health Economics and Outcomes Research, 2022
2022Atallah EL, Maegawa R, Latremouille-Viau D, Rossi C, Guérin A, Wu EQ, Patwardhan P
HEOR, Epidemiology & Market Access -
Chronic Myeloid Leukemia: Part II-Cost of Care Among Patients in Advanced Phases or Later Lines of Therapy in Chronic Phase in the United States from a Commercial Perspective
Journal of Health Economics and Outcomes Research, 2022
2022Atallah EL, Maegawa R, Latremouille-Viau D, Rossi C, Guérin A
HEOR, Epidemiology & Market Access -
Treatment patterns among children and adolescents with attention-deficit/hyperactivity disorder in the United States - a retrospective claims analysis
BMC Psychiatry, 2022
2022Schein J, Childress A, Adams J, Gagnon-Sanschagrin P, Maitland J, Qu W, Cloutier M, Guérin A
HEOR, Epidemiology & Market Access -
Economic burden of attention-deficit/hyperactivity disorder among children and adolescents in the United States: a societal perspective
Journal of Medical Economics, 2022
2022Schein J, Adler LA, Childress A, Cloutier M, Gagnon-Sanschagrin P, Davidson M, Kinkead F, Guerin A, Lefebvre P
HEOR, Epidemiology & Market Access -
The Economic Impact of Treatment Sequences for Chronic Lymphocytic Leukemia in the United States: A Cost of Care and Budget Impact Model of Venetoclax Plus Obinutuzumab Sequences
Journal of Clinical Pathways, 2022
2022Davids MS, Manzoor BS, Hazra NC, Fang H, Ravelo A, Han F, Guerin A, Sail K, Shapouri S, Shadman M
HEOR, Epidemiology & Market Access -
Reasons for treatment changes in adults with attention-deficit/hyperactivity disorder: a chart review study
BMC Psychiatry, 2022
2022Schein J, Childress A, Cloutier M, Desai U, Chin A, Simes M, Guerin A, Adams J
HEOR, Epidemiology & Market Access -
The Economic Burden of Posttraumatic Stress Disorder in the United States From a Societal Perspective
The Journal of Clinical Psychiatry, 2022
2022Davis LL, Schein J, Cloutier M, Gagnon-Sanschagrin P, Maitland J, Urganus A, Guerin A, Lefebvre P, Houle CR
HEOR, Epidemiology & Market Access -
Economic burden of attention-deficit/hyperactivity disorder among adults in the United States: a societal perspective
Journal of Managed Care & Specialty Pharmacy, 2022
2022Schein J, Adler LA, Childress A, Gagnon-Sanschagrin P, Davidson M, Kinkead F, Cloutier M, Guérin A, Lefebvre P
HEOR, Epidemiology & Market Access -
Opioid-Induced Constipation: Cost Impact of Approved Medications in the Emergency Department
Advances in Therapy, 2022
2022Peacock WF, Slatkin N, Gagnon-Sanschagrin P, Maitland J, Guérin A, Joseph G
HEOR, Epidemiology & Market Access -
Patient and Care Partner Burden in CKD Patients With and Without Anemia: A US-Based Survey
Kidney Medicine, 2022
2022Michalopoulos SN, Gauthier-Loiselle M, Aigbogun MS, Serra E, Bungay R, Clynes D, Cloutier M, Kahle E, Guérin A, Farag YMK, Wish JB
HEOR, Epidemiology & Market Access -
Reasons for Treatment Changes in Children and Adolescents with Attention-Deficit/Hyperactivity Disorder: A Chart Review Study
Advances in Therapy, 2022
2022Schein J, Cloutier M, Gauthier-Loiselle M, Bungay R, Guerin A, Childress A
HEOR, Epidemiology & Market Access -
Healthcare resource utilization and costs in patients with myelodysplastic syndromes treated with hypomethylating agents: a SEER-Medicare analysis
Journal of Medical Economics, 2021
2021Stein EM, Bonifacio G, Latrémouille-Viau D, Shi S, Guérin A, Wu EQ, Sadek I, Cao X
HEOR, Epidemiology & Market Access -
Economic burden of peanut allergy in pediatric patients with evidence of reactions to peanuts in the United States
Journal of Managed Care & Specialty Pharmacy, 2021
2021Blaiss MS, Meadows JA, Yu S, Robison DR, Hass SL, Norrett KE, Guerin A, Latremouille-Viau D, Tilles SA
HEOR, Epidemiology & Market Access -
Tyrosine kinase inhibitor therapy discontinuation in patients with chronic myeloid leukemia in chronic phase in the United States after clinical practice guideline updates
Leukemia & Lymphoma, 2021
2021Atallah EL, Sadek I, Maegawa R, Cao X, Latrémouille-Viau D, Pivneva I, Rossi C, Guérin A, Kota V
HEOR, Epidemiology & Market Access -
Disease Management and Outcomes in Patients Hospitalized for Acute Heart Failure in Japan
Cardiology and Therapy, 2021
2021Chen L, Ionescu-Ittu R, Romdhani H, Guérin A, Kessler P, Borentain M, Friend K, DeSouza M, Sato N
HEOR, Epidemiology & Market Access -
Treatment patterns among adults with attention-deficit/hyperactivity disorder in the United States: a retrospective claims study
Current Medical Research and Opinion, 2021
2021Schein J, Childress A, Adams J, Cloutier M, Gagnon-Sanschagrin P, Maitland J, Bungay R, Guérin A, Lefebvre P
HEOR, Epidemiology & Market Access -
Hospitalizations and healthcare costs associated with rifaximin versus lactulose treatment among commercially insured patients with hepatic encephalopathy in the United States
Journal of Medical Economics, 2021
2021Volk ML, Burne R, Guérin A, Shi S, Joseph GJ, Heimanson Z, Ahmad M
HEOR, Epidemiology & Market Access -
Treatment patterns and outcomes in patients with myelodysplastic syndromes treated with hypomethylating agents: a SEER-Medicare analysis
Leukemia & Lymphoma, 2021
2021Stein EM, Bonifacio G, Latremouille-Viau D, Shi S, Guerin A, Wu EQ, Sadek I, Cao X
HEOR, Epidemiology & Market Access -
Prevalence of post-traumatic stress disorder in the United States: a systematic literature review
Current Medical Research and Opinion, 2021
2021Schein J, Houle C, Urganus A, Cloutier M, Patterson-Lomba C, Wang Y, King S, Levinson W, Guérin A, Lefebvre P, Davis LL
HEOR, Epidemiology & Market Access -
Health-care resource utilization associated with peanut allergy management under allergen avoidance among commercially insured individuals
Allergy & Asthma Proceedings, 2021
2021Meadows JA, Yu S, Hass SL, Guerin A, Latremouille-Viau D, Tilles SA
HEOR, Epidemiology & Market Access -
Mental Health and Health-Related Quality of Life Among Nephrology Nurses: A Survey-Based Cross-Sectional Study
Nephrology Nursing Journal, 2021
2021Montoya V, Donnini K, Gauthier-Loiselle M, Sanon M, Cloutier M, Maitland J, Guérin A, Dutka P, Pryor L, Thomas-Hawkins C, Voegel A, Hoffmann M, Savin S, Kurzman A, Kear T
HEOR, Epidemiology & Market Access -
Costs associated with the administration of erythropoiesis-stimulating agents for the treatment of anemia in patients with non-dialysis-dependent chronic kidney disease: a US societal perspective
Journal of Managed Care & Specialty Pharmacy, 2021
2021Gauthier-Loiselle M, Michalopoulos SN, Cloutier M, Serra E, Bungay R, Szabo E, Guérin A
HEOR, Epidemiology & Market Access -
Excess healthcare costs in patients with autosomal dominant polycystic kidney disease by renal dysfunction stage
Journal of Medical Economics, 2021
2021Gagnon-Sanschagrin P, Liang Y, Sanon M, Oberdhan D, Guérin A, Cloutier M
HEOR, Epidemiology & Market Access -
Healthcare costs among patients with macular oedema associated with non-infectious uveitis: a US commercial payer's perspective
BMJ Open Opthalmology, 2021
2021Hariprasad SM, Joseph G, Gagnon-Sanschagrin P, Serra E, Bhattacharyya S, Bédard J, Guérin A, Albini TA
HEOR, Epidemiology & Market Access -
Impact of agitation in long-term care residents with dementia in the United States
International Journal of Geriatric Psychiatry, 2021
2021Fillit H, Aigbogun MS, Gagnon-Sanschagrin P, Cloutier M, Davidson M, Serra E, Guérin A, Baker RA, Houle CR, Grossberg G
HEOR, Epidemiology & Market Access -
Comparison of healthcare resource utilization and costs of patients with HR+/HER2- advanced breast cancer treated with ribociclib versus other CDK4/6 inhibitors
Journal of Medical Economics, 2021
2021Burne R, Balu S, Guérin A, Bungay R, Sin R, Paul ML
HEOR, Epidemiology & Market Access -
The societal economic burden of autosomal dominant polycystic kidney disease in the United States
BMC Health Services Research
2020Cloutier M, Manceur AM, Guerin A, Aigbogun MS, Oberdhan D, Gauthier-Loiselle M
HEOR, Epidemiology & Market Access -
In-hospital Therapy for Heart Failure with Reduced Ejection Fraction in the United States
Journal of the American College of Cardiology: Heart Failure, 2020
2020Greene SJ, Triana TS, Ionescu-Ittu R, Burne RM, Guérin A, Borentain M, Kessler PD, Tugcu A, DeSouza MM, Felker GM, Chen L
HEOR, Epidemiology & Market Access -
Real-World Treatment Patterns and Characteristics Among Patients with Agitation and Dementia in the United States: Findings from a Large, Observational, Retrospective Chart Review
Journal of Alzheimer's Disease, 2020
2020Aigbogun MS, Cloutier M, Gauthier-Loiselle M, Guerin A, Ladouceur M, Baker RA, Grundman M, Duffy RA, Hartry A, Gwin K, Fillit H
HEOR, Epidemiology & Market Access -
Vaso-occlusive crises and costs of sickle cell disease in patients with commercial, Medicaid, and Medicare insurance - the perspective of private and public payers
Journal of Medical Economics, 2020
2020Shah NR, Bhor M, Latremouille-Viau D, Sharma VK, Puckrein GA, Gagnon-Sanschagrin P, Khare A, Singh MK, Serra E, Davidson M, Xu L, Guerin A
HEOR, Epidemiology & Market Access -
Factors associated with more frequent diagnostic tests and procedures in patients with irritable bowel syndrome
Therapeutic Advances in Gastroenterology, January 1, 2019
2019Lacy B, Ayyagari R, Guérin A, Lopez A, Shi S, Luo M
HEOR, Epidemiology & Market Access -
Cost Effectiveness of Midostaurin in the Treatment of Newly Diagnosed FLT3-Mutated Acute Myeloid Leukemia in the United States
PharmacoEconomics. 2019 Feb;37(2):239-253
2019Stein E, Xie J, Duchesneau E, Bhattacharyya S, Vudumula U, Ndife B, Bonifacio G, Guérin A, Li N, Joseph G
HEOR, Epidemiology & Market Access -
Comparative Effectiveness of Non-cisplatin First-line Therapies for Metastatic Urothelial Carcinoma: Phase 2 IMvigor210 Study Versus US Patients Treated in the Veterans Health Administration
European Urology Oncology, 2019
2019Vander Velde N, Guerin A, Ionescu-Ittu R, Shi S, Wu EQ, Lin SW, Hsu LI, Saum KU, de Ducla S, Wang J, Li S, Thåström A, Liu S, Shi L, Leppert JT
HEOR, Epidemiology & Market Access -
Tyrosine kinase inhibitor therapy treatment and discontinuation in patients with chronic myeloid leukemia in chronic phase in the United States: a clinical practice perspective
Leukemia & Lymphoma, 2019
2019Ritchie EK, Latremouille-Viau D, Guerin A, Pivneva I, Habucky K, Ndife B, Joseph GJ, Atallah EL
HEOR, Epidemiology & Market Access -
Adjuvant therapy versus watch-and-wait post surgery for stage III melanoma: a multicountry retrospective chart review
Melanoma Management, 2019
2019Mohr P, Kiecker F, Soriano V, Dereure O, Mujika K, Saiag P, Utikal J, Koneru R, Robert C, Cuadros F, Chacón M, Villarroel RU, Najjar YG, Kottschade L, Couselo EM, Koruth R, Guérin A, Burne R, Ionescu-Ittu R, Perrinjaquet M, Zager JS
HEOR, Epidemiology & Market Access -
Second-line rituximab-bendamustine versus rituximab-gemcitabine-oxaliplatin in diffuse large B-cell lymphoma in the real world
Journal of Comparative Effectiveness Research, 2019
2019Ionescu-Ittu R, Shang A, Velde NV, Guerin A, Lin Y, Shi L, Shi S, Qayum N
HEOR, Epidemiology & Market Access -
Economic burden of relapse/recurrence in patients with major depressive disorder
Journal of Drug Assessment, 2019
2019Gauthier G, Mucha L, Shi S, Guerin A
HEOR, Epidemiology & Market Access -
Estimated Prevalence and Incidence of Dry Eye Disease Based on Coding Analysis of a Large, All-age United States Health Care System
American Journal of Ophthalmology, 2019
2019Dana R, Bradley JL, Guerin A, Pivneva I, Stillman IO, Evans AM, Schaumberg DA
HEOR, Epidemiology & Market Access -
Survival, Motor Function, and Motor Milestones: Comparison of AVXS-101 Relative to Nusinersen for the Treatment of Infants with Spinal Muscular Atrophy Type 1
Advances in Therapy, 2019
2019Dabbous O, Maru B, Jansen JP, Lorenzi M, Cloutier M, Guérin A, Pivneva I, Wu EQ, Arjunji R, Feltner D, Sproule DM
HEOR, Epidemiology & Market Access -
Institutionalization risk and costs associated with agitation in Alzheimer's disease
Alzheimer's & Dementia: Translational Research & Clinical Interventions, 2019
2019Cloutier M, Gauthier-Loiselle M, Gagnon-Sanschagrin P, Guerin A, Hartry A, Baker RA, Duffy R, Gwin K, Aigbogun MS
HEOR, Epidemiology & Market Access -
Dry eye disease ranking among common reasons for seeking eye care in a large US claims database
Clinical Ophthalmology, 2019
2019Bradley JL, Stillman IO, Pivneva I, Guerin A, Evans AM, Dana R
HEOR, Epidemiology & Market Access -
Economic analysis of BRAF gene mutation testing in real world practice using claims data: costs of single gene versus panel tests in patients with lung cancer
Journal of Medical Economics. Mar 8 2018:1-15
2018Dalal AA, Guerin A, Mutebi A, Culver KW
HEOR, Epidemiology & Market Access -
Increased Prevalence of Cancer in Adult Patients With Psoriasis in the United States: A Claims Based Analysis
J Drugs Dermatol. Feb 1 2018;17(2):180-186
2018Kimball AB, Sundaram M, Cloutier M, Gauthier-Loiselle M, Gagnon-Sanschagrin P, Guérin A, Ganguli A
HEOR, Epidemiology & Market Access -
Assessment of costs associated with adverse events in patients with cancer
PloS One. 2018;13(4):e0196007
2018Wong W, Yim YM, Kim A, Cloutier M, Gauthier-Loiselle M, Gagnon-Sanschagrin P, Guérin A
HEOR, Epidemiology & Market Access -
Prevalence of Psoriasis in Children and Adolescents in the United States: A Claims-Based Analysis
J Drugs Dermatol. Feb 1 2018;17(2):187-194
2018Paller AS, Singh R, Cloutier M, Gauthier-Loiselle M, Emond B, Guérin A, Ganguli A
HEOR, Epidemiology & Market Access -
Current Treatment Patterns Among Postmenopausal Women with HR+/HER2- Metastatic Breast Cancer in US Community Oncology Practices: An Observational Study
Advances in Therapy. 26 Mar 2018:1-12
2018Goldschmidt D, Dalal AA, Romdhani H, Kelkar S, Guerin A, Gauthier G, Wu EQ, Niravath P, Small T
HEOR, Epidemiology & Market Access -
Severe adverse events impact overall survival and costs in elderly patients with advanced non-small cell lung cancer on second-line therapy
Lung Cancer. May 2018;119:112-119
2018Borghaei H, Yim YM, Guerin A, Pivneva I, Shi S, Gandhi M, Ionescu-Ittu R
HEOR, Epidemiology & Market Access -
Economic Burden of HR+/HER2- Metastatic Breast Cancer Among Adult Premenopausal Women
Advances in Therapy. Mar 20 2018
2018Gauthier G, Gagnon-Sanschagrin P, Guérin A, Burne R, Small T, Niravath P, Dalal AA
-
Treatment patterns, healthcare resource utilization, and costs in patients with acute myeloid leukemia in commercially insured and Medicare populations
Journal of Medical Economics. 2018 Jun;21(6):556-563
2018Stein EM, Bonifacio G, Latremouille-Viau D, Guerin A, Shi S, Gagnon-Sanschagrin P, Briggs O, Joseph GJ
HEOR, Epidemiology & Market Access -
Reimbursement landscape for molecular testing in non-small cell lung cancer (NSCLC)
American Journal of Managed Care. Feb 19, 2018
2018Nellesen D, Dea K, Guerin A, Culver KW, Mutebi A, Dalal A
HEOR, Epidemiology & Market Access -
Treatment patterns, clinical and economic outcomes of patients with anaplastic lymphoma kinase-positive non-small cell lung cancer receiving ceritinib: a retrospective observational claims analysis
J Drug Assess. 2018;7(1):21-27
2018Dalal AA, Guerin A, Mutebi A, Culver KW
HEOR, Epidemiology & Market Access -
The risk of cardiovascular events in psoriasis patients treated with tumor necrosis factor-α inhibitors versus phototherapy: An observational cohort study
Journal of the American Academy of Dermatology. 2018 Jul;79(1):60-68
2018Wu JJ, Sundaram M, Cloutier M, Gauthier-Loiselle M, Guérin A, Singh R, Ganguli A
HEOR, Epidemiology & Market Access -
Dosing Patterns and Economic Burden of Palbociclib Drug Wastage in HR+/HER2- Metastatic Breast Cancer
Advances in Therapy. April 13, 2018
2018Dalal AA, Gagnon-Sanschagrin P, Burne R, Guérin A, Gauthier G, Small T, Niravath P
HEOR, Epidemiology & Market Access -
Assessing utility values for treatment-related health states of acute myeloid leukemia in the United States
Health and Quality of Life Outcomes. 2018 Sep 21;16(1):193
2018 -
Burden of Infections Among Chronic Myeloid Leukemia Patients Receiving Dasatinib or Nilotinib: A Real-World Retrospective Healthcare Claims Study in the United States
Advances in Therapy, 2018 Oct;35(10):1671-1685
2018Seiter K, Latrémouille-Viau D, Guérin A, Ndife B, Habucky K, Tang DH, Pivneva I, Gagnon-Sanschagrin P, Joseph GJ
HEOR, Epidemiology & Market Access -
The Comorbidity Burden of Hidradenitis Suppurativa in the United States: A Claims Data Analysis
Dermatology and Therapy. 2018 Dec;8(4):557-569
2018Kimball AB, Sundaram M, Gauthier G, Guérin A, Pivneva I, Singh R, Ganguli A
HEOR, Epidemiology & Market Access -
Monitoring of Hematologic, Cardiac, and Hepatic Function in Post-Menopausal Women with HR+/HER2- Metastatic Breast Cancer
Advances in Therapy. 2018 Aug;35(8):1251-1264
2018Guérin A, Goldschmidt D, Small T, Gagnon-Sanschagrin P, Romdhani H, Gauthier G, Kelkar S, Wu EQ, Niravath P, Dalal AA
HEOR, Epidemiology & Market Access -
Treatment and Monitoring Patterns Among Premenopausal Women with HR+/HER2- Advanced Breast Cancer
Advances in Therapy. 2018 Sep;35(9):1356-1367
2018Dalal AA, Gauthier G, Gagnon-Sanschagrin P, Burne R, Guérin A, Niravath P, Small T
HEOR, Epidemiology & Market Access -
A real-world analysis of healthcare costs and relative risk of hyperprolactinemia associated with antipsychotic treatments in the United States
Journal of Medical Economics. 2018 Dec;21(12):1183-1190
2018Cloutier M, Greene M, Touya M, Gagnon-Sanschagrin P, Guérin A
HEOR, Epidemiology & Market Access -
Adverse Medical Conditions Across Treatment Options in Patients With Psoriasis: A Claims-Based Analysis
Journal of Drugs in Dermatology, 2018
2018Wu J, Armstrong A, Singh R, Cloutier M, Gauthier-Loiselle M, Gagnon-Sanschagrin P, Arikan D, Fleischer A, Guérin A, Ganguli A
HEOR, Epidemiology & Market Access -
Health care resource utilization and costs in patients with chronic myeloid leukemia with better adherence to tyrosine kinase inhibitors and increased molecular monitoring frequency
Journal of Managed Care and Specialty Pharmacy. 2017;23(2):214-224
2017Latremouille-Viau D, Guerin A, Gagnon-Sanschagrin P, Dea K, Cohen BG, Joseph GJ
HEOR, Epidemiology & Market Access -
The economic burden of common adverse events associated with metastatic colorectal cancer treatment in the United States
Journal of Medical Economics. Jan 2017;20(1):54-62
2017Latremouille-Viau D, Chang J, Guerin A, Shi S, Wang E, Yu J, Ngai C.
HEOR, Epidemiology & Market Access -
Treatment patterns and healthcare costs among newly-diagnosed patients with chronic myeloid leukemia receiving dasatinib or nilotinib as first-line therapy in the United States
Journal of Medical Economics. Jan 2017;20(1):63-71
2017Latremouille-Viau D, Guerin A, Nitulescu R, Gagnon PS, Joseph GJ, Chen L.
-
Cost-effectiveness analysis of ocrelizumab versus subcutaneous interferon beta-1a for the treatment of relapsing multiple sclerosis
Journal of Medical Economics, 2017 October
2017Yang H, Duchesneau E, Foster R, Guérin A, Ma E, Thomas NP
HEOR, Epidemiology & Market Access -
Treatment Patterns and Early Outcomes of ALK-Positive Non-Small Cell Lung Cancer Patients Receiving Ceritinib: A Chart Review Study
Advances in Therapy. May 2017;34(5):1145-1156
2017Bendaly E, Dalal AA, Culver K, Galebach P, Bocharova I, Foster R, Sasane M, Macalalad AR, Guérin A
HEOR, Epidemiology & Market Access -
Monitoring for and Characterizing Crizotinib Progression: A Chart Review of ALK-Positive Non-Small Cell Lung Cancer Patients
Advances in Therapy. Jul 2017;34(7):1673-1685
2017Bendaly E, Dalal AA, Culver K, Galebach P, Bocharova I, Foster R, Sasane M, Macalalad AR, Guérin A
HEOR, Epidemiology & Market Access -
Readmission Risk in Chronic Obstructive Pulmonary Disease Patients: Comparative Study of Nebulized beta2-Agonists
Drugs Real World Outcomes. Mar 2017;4(1):33-41
2017Bollu V, Guérin A, Gauthier G, Hiscock R, Wu EQ
HEOR, Epidemiology & Market Access -
The economic burden of bipolar I disorder in the United States in 2015
Journal of Affective Disorders. Jan 15 2018;226:45-51
2017Cloutier M, Greene M, Guerin A, Touya M, Wu E
HEOR, Epidemiology & Market Access -
Number needed to treat and costs per responder among biologic treatments for moderate-to-severe plaque psoriasis in Japan
Journal of Dermatological Treatment. Feb 2018;29(1):24-31
2017Imafuku S, Nakano A, Dakeshita H, Li J, Betts KA, Guerin A
HEOR, Epidemiology & Market Access -
Overall survival in patients with glioblastoma before and after bevacizumab approval
Current Medical Research and Opinion. May 2018;34(5):813-820
2017Johnson DR, Omuro AMP, Ravelo A, Sommer N, Guerin A, Ionescu-Ittu R, Shi S, Macalalad A, Uhm J
HEOR, Epidemiology & Market Access -
Nilotinib versus dasatinib as second-line therapy in patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase who are resistant or intolerant to imatinib: a cost-effect
Journal of Medical Economics, 2017
2017Li N, Yang X, Fan L, Totev T, Guerin A, Chen L, Bhattacharyya S, Joseph G
HEOR, Epidemiology & Market Access -
Economic burden following allogeneic hematopoietic stem cell transplant in patients with diffuse large B-cell lymphoma
Leukemia and Lymphoma. May 2018;59(5):1133-1142
2017Maziarz RT, Hao Y, Guerin A, Gauthier G, Gauthier-Loiselle M, Thomas SK, Eldjerou L
HEOR, Epidemiology & Market Access -
Cardiovascular event risk assessment in psoriasis patients treated with tumor necrosis factor-alpha inhibitors versus methotrexate
Journal of the American Academy of Dermatology. Jan 2017;76(1):81-90
2017Wu JJ, Guérin A, Sundaram M, Dea K, Cloutier M, Mulani P
HEOR, Epidemiology & Market Access -
Role of Cost-Sharing Subsidies on the Initiation of and Adherence to Tyrosine Kinase Inhibitor Therapy by Medicare Beneficiaries with Chronic Myeloid Leukemia
Journal of Clinical Oncology. May 20 2017;35(15):1744-1745
2017Ritchie EK, Guerin A, Wolff J, Joseph G
HEOR, Epidemiology & Market Access -
Treatment patterns, healthcare resource utilization, and costs following first-line antidepressant treatment in major depressive disorder: a retrospective US claims database analysis
BMC Psychiatry. Jun 19 2017;17(1):222
2017Gauthier G, Guérin A, Zhdanava M, Jacobson W, Nomikos G, Merikle E, François C, Perez V
HEOR, Epidemiology & Market Access -
The economic burden of common adverse events associated with metastatic colorectal cancer treatment (1)
Journal of Medical Economics. Jan 2017;20(1):54-62
2017Latremouille-Viau D, Chang J, Guerin A, Shi S, Wang E, Yu J, Ngai C
HEOR, Epidemiology & Market Access -
Treatment patterns and healthcare costs among newly-diagnosed patients with chronic myeloid leukemia(1)
Journal of Medical Economics. Jan 2017;20(1):63-71
2017Latremouille-Viau D, Guerin A, Nitulescu R, Gagnon PS, Joseph GJ, Chen L
HEOR, Epidemiology & Market Access -
Healthcare resource utilization, healthcare costs and dose escalation in psoriasis patients initiated on ustekinumab versus adalimumab: a retrospective claim study
Journal of Dermatological Treatment. Jun 2017;28(4):290-298
2017Wu JJ, Guérin A, Gauthier G, Sundaram M
HEOR, Epidemiology & Market Access -
Cost-effectiveness analysis of ocrelizumab versus subcutaneous interferon beta-1a for the treatment (1)
Journal of Medical Economics. Oct 2017;20(10):1056-1065
2017Yang H, Duchesneau E, Foster R, Guerin A, Ma E, Thomas NP
HEOR, Epidemiology & Market Access -
The Economic Burden of Schizophrenia in the United States in 2013
Journal of Clinical Psychiatry, June 2016;77(6):764-71
HEOR, Epidemiology & Market Access
2016 -
Real-World Analysis of Medical Costs and Healthcare Resource Utilization in Elderly Women with HR+/HER2- Metastatic Breast Cancer Receiving Everolimus-Based Therapy or Chemotherapy
Advances in Therapy, 2016 May
2016Hao Y, Li N, Fang AP, Koo V, Peeples M, Kageleiry A, Wu EQ, Guerin A
HEOR, Epidemiology & Market Access -
Treatment patterns and factors associated with the use of everolimus among post-menopausal women with HR+/HER2- metastatic breast cancer: a retrospective US claims study
Expert Opinion on Pharmacotherapy, 2016 04; 17(9): 1189-1196. e-pub ahead of print 2016/04/08
2016Guerin A, Hao Y, Tang D, Peeples M, Fang A, Kageleiry A, Koo V, Li N, Wu EQ.
HEOR, Epidemiology & Market Access -
Comparison of medical costs and healthcare resource utilization of post-menopausal women with HR+/HER2- metastatic breast cancer receiving everolimus-based therapy or chemotherapy: a retrospective cla
Journal of Medical Economics, 2016 19(4): 414-423
2016Li N, Hao Y, Koo V, Fang A, Peeples M, Kageleiry A, Wu EQ, Guerin A.
-
Time on treatment of everolimus and chemotherapy among postmenopausal women with hormone-receptor-positive/human-epidermal-growth-factor-receptor-2-negative metastatic breast cancer: A retrospective c
Current Medical Research and Opinion, 2016 02; 32(2): 385-394
2016Li N, Hao Y, Kageleiry A, Peeples M, Fang A, Koo V, Wu EQ, Guerin A.
HEOR, Epidemiology & Market Access -
Healthcare Resource Utilization, Healthcare Costs, and Dose Escalation in Psoriasis Patients Initiated on Ustekinumab versus Adalimumab: A Retrospective Claim Study
Journal of Dermatological Treatment, 2016 10: 1-23. doi: 10.1080/09546634.2016.1247946
2016Wu JJ, Guerin A, Gauthier G, Sundaram M
-
Treatment patterns, overall survival, healthcare resource use and costs in elderly Medicare beneficiaries with chronic myeloid leukemia using second-generation tyrosine kinase inhibitors as second-lin
Current Medical Research and Opinion, 2016 32(5): 817-827. e-pub ahead of print 2016/01/09
2016Smith BD, Liu J, Latremouille-Viau D, Guerin A, Fernandez D, Chen L.
HEOR, Epidemiology & Market Access -
Survival in patients with non-metastatic breast cancer treated with adjuvant trastuzumab in clinical practice
SpringerPlus, 2016 03; 5: 395. e-pub ahead of print 2016/04/06
2016Gallagher CM, More K, Masaquel A, Kamath T, Guerin A, Ionescu-Ittu R, Nitulescu R, Gauthier-Loiselle M, Sicignano N, Butts E, Wu EQ, Barnett B
HEOR, Epidemiology & Market Access -
Delay in initiation of adjuvant trastuzumab therapy leads to decreased overall survival and relapse-free survival in patients with HER2-positive non-metastatic breast cancer
Breast Cancer Research and Treatment, 2016 05; 157(1): 145-156. e-pub ahead of print 2016/04/25
2016Gallagher CM, More K, Kamath T, Masaquel A, Guerin A, Ionescu-Ittu R, Gauthier-Loiselle M, Nitulescu R, Sicignano N, Butts E, Wu EQ, Barnett B
HEOR, Epidemiology & Market Access -
Treatment patterns and outcomes in BRAF V600E-mutant melanoma patients with brain metastases receiving vemurafenib in the real-world setting
Cancer Med. 2015 May 20. doi: 10.1002/cam4.475. [Epub ahead of print]
2015Gibney GT, Gauthier G, Ayas C, Galebach P, Wu EQ, Abhyankar S, Reyes C, Guerin A, Yim YM
HEOR, Epidemiology & Market Access -
ALK rearrangement testing and treatment patterns for patients with ALK-positive non-small cell lung cancer
Cancer Epidemiol. 2015 Jun;39(3):307-12
2015Guerin A, Sasane M, Zhang J, Macalalad AR, Galebach P, Jarvis J, Kageleiry A, Culver K, Wu EQ, Wakelee H
HEOR, Epidemiology & Market Access -
Psoriasis and risk of diabetes-associated microvascular and macrovascular complications
J Am Acad Dermatol. 2015 Jun;72(6):968-977.e2
2015Armstrong AW, Guerin A, Sundaram M, Wu EQ, Faust ES, Ionescu-Ittu R, Mulani P
HEOR, Epidemiology & Market Access -
Treatment persistence in attention deficit/hyperactivity disorder: a retrospective analysis of patients initiated on lisdexamfetamine vs other medications
J Med Econ. 2013 Nov;16(11):1275-89
2015Setyawan J, Guerin A, Hodgkins P, Gauthier G, Cloutier M, Wu E, Erder MH
HEOR, Epidemiology & Market Access -
The economic burden of gastrointestinal stromal tumor (GIST) recurrence in patients who have received adjuvant imatinib therapy
J Med Econ. 2015 Mar;18(3):241-8
2015Guerin A, Sasane M, Gauthier G, Keir CH, Zhdavana M, Wu EQ
HEOR, Epidemiology & Market Access -
Real-world treatment patterns of gout patients treated with colchicine or other common treatments for gout in acute care settings: a retrospective chart review study
Current Medical Research and Opinion. 2015
2015Shiozawa A, Cloutier M, Heroux J, Guerin A, Wu EQ, Jackson R
HEOR, Epidemiology & Market Access -
Comparison of survival and hospitalization rates between Medicare patients with advanced NSCLC treated with bevacizumab-carboplatin-paclitaxel and carboplatin-paclitaxel: a retrospective cohort study
Lung Cancer. 2014 Dec;86(3):350-7
2014Langer C, Ravelo A, Hazard SJ, Guerin A, Ionescu-Ittu R, Latremouille-Viau D, Wu EQ, Ramalingam S
HEOR, Epidemiology & Market Access -
Investigation of adverse-event-related costs for patients with metastatic breast cancer in a real-world setting
Oncologist. 2014 Sep;19(9):901-8
2014Hurvitz S, Guerin A, Brammer M, Guardino E, Zhou ZY, Latremouille Viau D, Wu EQ, Lalla D
HEOR, Epidemiology & Market Access -
The impact of moderate-to-severe Crohn's Disease on employees' salary growth
Inflamm Bowel Dis. 2014 Oct;20(10):1734-8
2014Loftus EV Jr, Skup M, Ozbay AB, Wu E, Guerin A, Chao J, Mulani P
HEOR, Epidemiology & Market Access -
Impact of low-grade adverse events on health-related quality of life in adult patients receiving imatinib or nilotinib for newly diagnosed Philadelphia chromosome positive chronic myelogenous leukemia
Curr Med Res Opin. 2014 Nov;30(11):2317-28
2014Guerin A, Chen L, Ionescu-Ittu R, Marynchenko M, Nitulescu R, Hiscock R, Keir C, Wu EQ
HEOR, Epidemiology & Market Access -
Distribution and drivers of costs in type 2 diabetes mellitus treated with oral hypoglycemic agents: a retrospective claims data analysis
J Med Econ. 2014 Sep;17(9):646-57
2014Bron M, Guerin A, Latremouille-Viau D, Ionescu-Ittu R, Viswanathan P, Lopez C, Wu EQ
HEOR, Epidemiology & Market Access -
Risk of developing colorectal cancer and benign colorectal neoplasm in patients with chronic constipation
Aliment Pharmacol Ther. 2014 Jul;40(1):83-92
2014Guerin A, Mody R, Fok B, Lasch KL, Zhou Z, Wu EQ, Zhou W, Talley NJ
HEOR, Epidemiology & Market Access -
Association between regular molecular monitoring and tyrosine kinase inhibitor therapy adherence in chronic myelogenous leukemia in the chronic phase
Curr Med Res Opin. 2014 Jul;30(7):1345-52
2014Guerin A, Chen L, Dea K, Wu EQ, Goldberg SL
HEOR, Epidemiology & Market Access -
Economic benefits of adequate molecular monitoring in patients with chronic myelogenous leukemia
J Med Econ. 2014 Feb;17(2):89-98
2014Guerin A, Chen L, Dea K, Wu EQ, Goldberg SL
HEOR, Epidemiology & Market Access -
Comparison of treatment patterns and economic outcomes in metastatic breast cancer patients initiated on trastuzumab versus lapatinib: a retrospective analysis
Springerplus. 2014 May 8;3:236
2014Guerin A, Lalla D, Gauthier G, Styles A, Wu EQ, Masaquel A, Brammer MG
HEOR, Epidemiology & Market Access -
Treatment patterns, prescribing decision drivers, and predictors of complete response following disease recurrence in gastrointestinal stromal tumor patients-a chart extract-based approach
J Gastrointest Cancer. 2014 Dec;45(4):431-40
2014Conley AP, Guerin A, Sasane M, Gauthier G, Schwiep F, Keir CH, Wu EQ
HEOR, Epidemiology & Market Access -
Impact of timely switching from imatinib to a second-generation tyrosine kinase inhibitor after 12-month complete cytogenetic response failure: a chart review analysis
Clinical Lymphoma, Myeloma & Leukemia, 2014
2014DeAngelo DJ, Chen L, Guerin A, Styles A, Giguere-Duval P, Wu EQ
HEOR, Epidemiology & Market Access -
Association between molecular monitoring and long-term outcomes in chronic myelogenous leukemia patients treated with first line imatinib
Curr Med Res Opin. 2013 Sep;29(9):1075-82
2013Goldberg SL, Chen L, Guerin A, Macalalad AR, Liu N, Kaminsky M, Ericson SG, Wu EQ
HEOR, Epidemiology & Market Access -
A longitudinal analysis of costs associated with change in disease activity in systemic lupus erythematosus
J Med Econ. 2013;16(6):793-800
2013Kan H, Guerin A, Kaminsky MS, Yu AP, Wu EQ, Denio A, Priti J, Narayanan S, Molta C
HEOR, Epidemiology & Market Access -
Comparison of the long-term risk of recurrence and other clinical outcomes in GIST patients receiving imatinib as adjuvant therapy--a retrospective chart extract-based approach
J Gastrointest Cancer. 2013 Jun;44(2):190-8
2013Conley AP, Guerin A, Sasane M, Gauthier G, Schwiep F, Keir CH, Wu EQ
HEOR, Epidemiology & Market Access -
Outcomes in atrial fibrillation patients on combined warfarin & antiarrhythmic therapy
Int J Cardiol. 2013 Jul 31;167(2):564-9
2013Guerin A, Lin J, Jhaveri M, Wu EQ, Yu AP, Cloutier M, Gauthier G, Alpert JS
HEOR, Epidemiology & Market Access -
Comparison of therapy augmentation and deviation rates from the recommended once-daily dosing regimen between LDX and commonly prescribed long-acting stimulants for the treatment of ADHD in youth and
J Med Econ. 2013 Oct;16(10):1203-15
2013Setyawan J, Hodgkins P, Guerin A, Gauthier G, Cloutier M, Wu E, Erder MH
HEOR, Epidemiology & Market Access -
Comparing treatment adherence of lisdexamfetamine and other medications for the treatment of attention deficit/hyperactivity disorder: a retrospective analysis
J Med Econ. 2013 Jul;16(7):962-75
2013Setyawan J, Hodgkins P, Guerin A, Gauthier G, Cloutier M, Wu EQ, Erder MH
HEOR, Epidemiology & Market Access -
Comparing nilotinib with dasatinib as second-line therapies in patients with chronic myelogenous leukemia resistant or intolerant to imatinib – a retrospective chart review analysis
Current Medical Research and Opinion, 2013
2013Griffin JD, Guerin A, Chen L, Macalalad AR, Luo J, Ionescu-Ittu R, Wu EQ
HEOR, Epidemiology & Market Access -
Risks of developing psychiatric disorders in pediatric patients with psoriasis
J Am Acad Dermatol. 2012 Jan 11.
2012Kimball A, Wu EQ, Guérin A, Yu AP, Tsaneva M, Gupta S, Bao Y, Mulani P
HEOR, Epidemiology & Market Access -
Comorbidity burden, healthcare resource utilization, and costs in chronic gout patients refractory to conventional urate-lowering therapy
2012 Nov;19(6):e157-66
2012Wu EQ, Forsythe A, Guerin A, Yu AP, Latremouille-Viau D, Tsaneva M
HEOR, Epidemiology & Market Access -
Economic burden of dermatologic adverse drug reactions in the treatment of colorectal, non-small cell lung, and head and neck cancers
Journal of Medical Economics, 1-30, November 27, 2012
2012Ray S, Bonthapally V, Holen K, Gauthier G, Wu EQ, Cloutier M, Guérin A
HEOR, Epidemiology & Market Access -
Clinical outcomes, quality of life, and costs associated with implantation of vagus nerve stimulation therapy
European Journal of Paediatric Neurology, September 2012, Vol. 16, No. 5
2012Helmers SL, Duh MS, Guerin A, Sarda SP, Samuelson TM, Bunker MT, Olin BD, Jackson SD, Faught E
HEOR, Epidemiology & Market Access -
Sleep quality and other patient-reported outcomes improve after patients with psoriasis with suboptimal response to other systemic therapies are switched to adalimumab: results from PROGRESS, an open-
Br J Dermatol. 2012 Dec; 167(6):1374-81
2012Strober BE, Sobell JM, Duffin KC, Bao Y, Guerin A, Yang H, Goldblum O, Okun MM, Mulani PM
HEOR, Epidemiology & Market Access -
Monitoring and switching patterns of patients with chronic myeloid leukemia treated with imatinib in community settings: a chart review analysis
Current Medical Research and Opinion, 2012
2012Chen L, Guérin A, Xie J, Wu EQ, Yu AP, Ericson SG, Jabbour E
HEOR, Epidemiology & Market Access -
Efficacy and safety of adalimumab among patients with moderate to severe psoriasis with co-morbidities
Am J Clin Dermatol. 2011 Feb 1;12(1):51-62
2011Kimball A, Bensimon A, Guerin A, Yu AP, Wu EQ, Okun M, Bao Y, Gupta S, Mulani P
HEOR, Epidemiology & Market Access -
Economic burden of comorbidities in patients with psoriasis is substantial
J Eur Acad Dermatol Venereol. 2011 Feb; 25(2):157-63. Epub 2010 Jun 17.
2011Kimball A, Guerin A, Tsaneva M, Yu AP, Wu EQ, Gupta S, Bao Y, Mulani P
HEOR, Epidemiology & Market Access -
Mortality and Nonadherence to AEDS
Sudden Unexpected Death in Epilepsy: Continuing the Global Conversation (Epilepsy Australia, Epilepsy Bereaved, and SUDEP Aware/North America, 2011)
2011Duh MS, Greenberg PE, Guerin A, Korves C
HEOR, Epidemiology & Market Access -
Health-related quality of life in patients with advanced renal cell carcinoma receiving pazopanib or placebo in a randomised phase III trial
Eur J Cancer. 2011 Jun 18.
2011Cella D, Pickard A, Duh MS, Guerin A, Mishagina N, Antras L, Neary M, McCann L, Hodge R, Sternberg CN
HEOR, Epidemiology & Market Access -
Increased risks of developing anxiety and depression in young patients with Crohn's disease
Am J Gastroenterol. 2011 Sep;106(9):1670-7. doi: 10.1038/ajg.2011.142. Epub 2011 May 3.
2011Loftus E Jr, Guerin A, Yu AP, Wu EQ, Yang M, Chao J, Mulani P
HEOR, Epidemiology & Market Access -
Clinical and economic impact of vagus nerve stimulation therapy in patients with drug-resistant epilepsy
Epilepsy Behav. 2011 Oct;22(2):370-5.
2011Helmers S, Duh MS, Guerin A, Sarda S, Samuelson T, Bunker M, Olin B, Jackson S, Faught E
HEOR, Epidemiology & Market Access -
Clinical and economic outcomes of multiple versus single long-acting inhalers in COPD
Respir Med. 2011 Dec;105(12):1861-71. Epub 2011 Jul 31.
2011Yu AP, Guerin A, de Leon DP, Ramakrishnan K, Wu EQ, Mocarski M, Blum S, Setyawan J
HEOR, Epidemiology & Market Access -
Therapy persistence and adherence in patients with chronic obstructive pulmonary disease: multiple versus single long-acting maintenance inhalers
J Med Econ. 2011;14(4):486-96. Epub 2011 Jun 16.
2011Yu AP, Guerin A, Ponce de Leon D, Ramakrishnan K, Wu EQ, Mocarski M, Blum S, Setyawan J
HEOR, Epidemiology & Market Access -
Epidemiologic evaluation of cardiovascular risk in patients receiving milnacipran, venlafaxine, or amitriptyline: evidence from French health data
Ann Pharmacother. 2011 Feb 8.
2011Mease PJ, Zimetbaum PJ, Duh MS, Vekeman F, Guerin A, Boerstoel-Streefland M, Jiang W, Lefebvre P
HEOR, Epidemiology & Market Access -
Coronary heart disease and stroke risk in patients with psoriasis: retrospective analysis
Am J Med. 2010 Apr;123(4):350-7
2010Kimball A, Guerin A, Latremouille-Viau D, Yu A, Gupta S, Bao Y, Mulani P
HEOR, Epidemiology & Market Access -
High prevalence of potential drug-drug interactions for psoriasis patients prescribed methotrexate or cyclosporine for psoriasis
Dermatology. 2010;220(2):128-37. Epub 2010 Feb 3
2010Saurat J, Guerin A, Yu A, Latremouille-Viau D, Wu E, Gupta S, Bao Y, Mulani P
HEOR, Epidemiology & Market Access -
Perceptions and prescribing considerations among US psychiatrists regarding drug–drug interactions associated with oral atypical antipsychotics
Current Medical Research and Opinion 2010, Pages 2735-2744. Published online 11/01/2010; doi:10.1185/03007995.2010.530159
2010Frois C, Guerin A, Saraogi A, Panish J, Dirani R
HEOR, Epidemiology & Market Access -
Retrospective real-world comparison of medical visits, costs, and adherence between nilotinib and dasatinib in chronic myeloid leukemia
Current Medical and Research Opinion, December 2010, Vol. 26, No. 12 , Pages 2861-2869
2010Wu EQ, Guerin A, Yu A, Bollu V, Guo A, Griffin J
HEOR, Epidemiology & Market Access -
Impact of nonadherence to antiepileptic drugs on health care utilization and costs: findings from the RANSOM study
Epilepsia, 2009 Mar
2009Faught RE, Weiner JR, Guerin A, Cunnington MC, Duh M
HEOR, Epidemiology & Market Access
-
May 8, 2023
Analysis Group Abstract to Be Featured as a Lecture Presentation at Digestive Disease Week 2023
Event: Digestive Disease Week 2023
Host: Digestive Disease Week -
May 31, 2024
Analysis Group to Present New Outcomes Research at 2024 ASCO Annual Meeting
Event: 2024 ASCO Annual Meeting
Host: American Society of Clinical Oncology (ASCO)
-
December 4, 2024
-
August 27, 2024
-
June 14, 2024
-
June 4, 2024
-
February 26, 2024
-
December 1, 2023
-
October 23, 2023
-
July 6, 2023
-
March 22, 2023
-
December 7, 2022
-
October 17, 2022
![Annie Guérin](/globalassets/experts-and-consultants/managing-principals/guerin_annie.jpg)